Antibiotics, Dosing, and CFTR

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what additional effect might CFTR modulation have on dosing decisions?

That’s the topic Dr. Andrea Hahn, Assistant Professor of Pediatrics and an Infectious Disease Specialist at Children’s National Medical Center and George Washington University School of Medicine and Health Sciences, addresses in this eCysticFibrosis Review podcast. 

The Current State of CFTR Modification

Volume 6, Issue 2.

In this issue we are joined by one of our Program Directors, Dr. Noah Lechtzin from the Johns Hopkins University. Dr. Lechtzin will address the current state of CFTR modification and how it can be applied in practice.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Breaking Coverage of CAT trial

Special Edition 2015, Part 4.

Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Stuart Elborn of Queen’s University in Belfast, Ireland. Dr. Elborn discusses the implications of the CAT study and how it effects his practice.

Breaking Coverage of CAT trial

Special Edition 2015, Part 3.

Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. JP Clancy of Cincinnati Children’s Hospital. Dr. Clancy discusses the implications of the CAT study and how it effect his practice.

Breaking Coverage of CAT trial

Special Edition 2015, Part 2.

Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Scott Bell of the QIMR Berghofer Medical Research Institute. Dr. Bell discusses the implications of the CAT study and how it will effect his practice.

Breaking Coverage of CAT trial

Special Edition 2015, Part 1.

Join us as Dr. Peter Mogayzel of the Johns Hopkins University discusses the design and findings for the CAT study with Dr. Patrick Flume of the Medical University of South Carolina. Learn about the importance of the study and how it may effect your practice.

Agents for the management of Pseudomonas aeruginosa infection

Volume 5, Issue 14.

In this issue we are joined by Dr. Shawn Aaron of University of Ottawa in Ontario, Canada. Dr. Aaron will discuss infection in patients with optimal therapy of chronic Pseudomonas aeruginosa cystic fibrosis, describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibrosis, and evaluate the optimal choice of antibiotics to treat Pseudomonas-associated pulmonary exacerbations in patients with cystic fibrosis.

Featured Cases: Exacerbation Therapies

Volume 3, Issue 4.

This podcast has been developed for clinicians caring for patients with issues related to cystic fibrosis. You can also read the companion newsletter. In this edition Dr. Chris Goss will explain the use of new inhalation therapies for the treatment of cystic fibrosis, with the discussion some typical case scenarios.